Adrenergic receptor agonists are a class of drugs that activate adrenergic receptors, which are found throughout the body and mediate the effects of the sympathetic nervous system. These receptors include alpha-adrenergic receptors and beta-adrenergic receptors. When adrenergic agonists bind to these receptors, they mimic the action of the sympathetic nervous system's neurotransmitters, such as adrenaline and noradrenaline. This leads to various physiological responses, such as increased heart rate, bronchodilation, and vasoconstriction. Due to their diverse effects on the cardiovascular and respiratory systems, adrenergic receptor agonists are used to treat several medical conditions. Asthma and chronic obstructive pulmonary disease (COPD) patients benefit from bronchodilators like salbutamol, which activate beta-2 adrenergic receptors, promoting smooth muscle relaxation in the airways. In cases of anaphylactic shock, epinephrine (adrenaline) acts as an alpha and beta-adrenergic receptor agonist, swiftly counteracting severe allergic reactions. Additionally, adrenergic agonists increase blood pressure in critically ill patients, where dopamine serves as a vital agent. According to the World Health Organization (WHO), asthma affects approximately 339 million people worldwide. Hence, adrenergic receptor agonists play a pivotal role in managing this prevalent respiratory condition, significantly improving patients' quality of life. The development and launch of newer products by the market players will substantially enhance the revenue of the Adrenergic Receptor Agonists market over the forecast years.
Several of these inhibitors are on the market, while many are in ongoing clinical trials. Ten companies in their pipelines have 18 products in various stages of clinical trials. One product is in Phase 4, 7 products are in Phase 2, and 1 development is in Phase 1 of the clinical trials.
Approved molecules
- Mirvaso (brimonidine tartrate)
Drugs in Pipeline
- Ar08
- Aceclidine/Tropicamide (Prx-100)
- D-Amphetamine Transdermal Drug Delivery System (D-Ats)
- Dextroamphetamine Modified Release (Hld-100)
- Adzenys Xr-Odt (Amphetamine Extended-Release Orally Disintegrating Tablets)
- Phenylephrine Topical Gel (Psd503)
- Clonidine/Oxybutynin (Op-014)
Clinical Activity and Developments of Adrenergic Receptor Agonists
As of July 2023, 17 products for 82 diseases are in 117 clinical trials. For instance,
- Wake Forest University Health Sciences is conducting a Phase 4 investigational study to investigate internet surveys and their impact on adherence and quality of life to Mirvaso for Rosacea that was expected to complete by June 2017.
- Thomas Jefferson University is conducting a Phase 4 clinical trial to investigate low-dose Vasopressin vs Phenylephrine in cardiac surgery that is expected to complete by November 2023.
- The University of Chicago is conducting a Phase 4 clinical trial to evaluate Vasoactive drugs for the management of Shock in the ICU that is expected to complete by December 2023.
|
Molecule name |
Number of studies |
|
Mirvaso (brimonidine tartrate) |
27 |
|
AR08 |
2 |
|
aceclidine/tropicamide (PRX-100) |
2 |
|
d-amphetamine transdermal drug delivery system (d-ATS) |
2 |
|
dextroamphetamine modified release (HLD-100) |
2 |
Target Indication Analysis of Adrenergic Receptor Agonists
Adrenergic receptor agonists are utilized in various medical conditions due to their ability to activate adrenergic receptors and produce specific physiological responses. One of the most common indications is the management of asthma and chronic obstructive pulmonary disease (COPD). Beta-2 adrenergic agonists like salbutamol are the primary choice in these respiratory disorders, as they induce bronchodilation, alleviating airway constriction and improving breathing. Additionally, adrenergic agonists play a crucial role in treating anaphylactic shock, where epinephrine (adrenaline) acts rapidly to counteract severe allergic reactions by stimulating alpha and beta-adrenergic receptors. In the field of cardiovascular medicine, adrenergic agonists like dopamine are employed to increase blood pressure in critically ill patients, while isoproterenol is used in specific cases of bradycardia. Moreover, these agonists find application in ophthalmology for conditions like glaucoma, where epinephrine reduces intraocular pressure. Lastly, adrenergic receptor agonists also control nasal congestion in cold and allergy medications, providing symptomatic relief for patients.
Adrenergic Receptor Agonists Regional Analysis
Adrenergic Receptor Agonists Market
The U.S. Department of Health and Human Services reports the prevalence of Asthma in the USA to be 7.7% in 2021, with a plurality of 8% and 6.6% amongst adults and children, respectively. According to the Asthma and Allergy Foundation of America, in 2021, about 25 million people suffered from Asthma (about 1 in every 13 Americans). About 5 million American children have asthma, according to the same report. Because of many genetic, environmental, and occupational risk factors, asthma prevalence varies greatly across the globe. Asthma is thought to affect 334 million people worldwide now which is responsible for 250,000 fatalities annually. According to the WHO, asthma claimed the lives of 455 000 people in 2019, affecting an estimated 262 million people.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Mirvaso (brimonidine tartrate) has been approved by the FDA.
These are being used in various indications like Glaucoma, Raynaulds disease, Asthma, COPD, and others.
Galderma, Arbor c Pharmaceuticals LLC, LENZ Therapeutics, Takeda Pharmaceutical, and Highland Therapeutics are some of the major market players for Adrenergic Receptor Agonists.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to different types of disorders like Asthma, COPD, and Weight gain are the key opportunities for Adrenergic Receptor Agonists in the market.
- Galderma
- Arbor c Pharmaceuticals LLC
- LENZ Therapeutics
- Takeda Pharmaceutical
- Highland Therapeutics
- Aytu BioPharma
- Regent Pacific Group
- Orient Europharma